Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.

Elias Jabbour, Jorge E. Cortés, Hagop Kantarjian

Research output: Contribution to journalReview article

Abstract

Chronic myeloid leukemia (CML) is characterized at the molecular level by the presence of the Philadelphia chromosome (Ph) and the resultant oncogenic signaling by the BCR-ABL fusion protein. The treatment and outlook for CML were revolutionized by the introduction of imatinib, but resistance is a substantial barrier to successful treatment in many patients. Introduction of the second-generation tyrosine kinase inhibitors (TKI) dasatinib and nilotinib has provided effective therapeutic options for many patients with resistance to front-line imatinib. However, the T315I mutation remains a significant clinical issue because it is insensitive to all currently available agents. A number of new agents are in development and many hold the promise of activity in T315I-mutated disease. Successful treatment of patients with disease harboring T315I might lie in the effective combination or sequencing of these new agents with existing TKI therapies.

Original languageEnglish (US)
Pages (from-to)S272-279
JournalClinical lymphoma & myeloma
Volume9 Suppl 3
StatePublished - 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics
Philadelphia Chromosome
Imatinib Mesylate
Mutation
Proteins

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. / Jabbour, Elias; Cortés, Jorge E.; Kantarjian, Hagop.

In: Clinical lymphoma & myeloma, Vol. 9 Suppl 3, 2009, p. S272-279.

Research output: Contribution to journalReview article

@article{97d68400d484432db5cae7fd60394ad8,
title = "Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.",
abstract = "Chronic myeloid leukemia (CML) is characterized at the molecular level by the presence of the Philadelphia chromosome (Ph) and the resultant oncogenic signaling by the BCR-ABL fusion protein. The treatment and outlook for CML were revolutionized by the introduction of imatinib, but resistance is a substantial barrier to successful treatment in many patients. Introduction of the second-generation tyrosine kinase inhibitors (TKI) dasatinib and nilotinib has provided effective therapeutic options for many patients with resistance to front-line imatinib. However, the T315I mutation remains a significant clinical issue because it is insensitive to all currently available agents. A number of new agents are in development and many hold the promise of activity in T315I-mutated disease. Successful treatment of patients with disease harboring T315I might lie in the effective combination or sequencing of these new agents with existing TKI therapies.",
author = "Elias Jabbour and Cort{\'e}s, {Jorge E.} and Hagop Kantarjian",
year = "2009",
language = "English (US)",
volume = "9 Suppl 3",
pages = "S272--279",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.

AU - Jabbour, Elias

AU - Cortés, Jorge E.

AU - Kantarjian, Hagop

PY - 2009

Y1 - 2009

N2 - Chronic myeloid leukemia (CML) is characterized at the molecular level by the presence of the Philadelphia chromosome (Ph) and the resultant oncogenic signaling by the BCR-ABL fusion protein. The treatment and outlook for CML were revolutionized by the introduction of imatinib, but resistance is a substantial barrier to successful treatment in many patients. Introduction of the second-generation tyrosine kinase inhibitors (TKI) dasatinib and nilotinib has provided effective therapeutic options for many patients with resistance to front-line imatinib. However, the T315I mutation remains a significant clinical issue because it is insensitive to all currently available agents. A number of new agents are in development and many hold the promise of activity in T315I-mutated disease. Successful treatment of patients with disease harboring T315I might lie in the effective combination or sequencing of these new agents with existing TKI therapies.

AB - Chronic myeloid leukemia (CML) is characterized at the molecular level by the presence of the Philadelphia chromosome (Ph) and the resultant oncogenic signaling by the BCR-ABL fusion protein. The treatment and outlook for CML were revolutionized by the introduction of imatinib, but resistance is a substantial barrier to successful treatment in many patients. Introduction of the second-generation tyrosine kinase inhibitors (TKI) dasatinib and nilotinib has provided effective therapeutic options for many patients with resistance to front-line imatinib. However, the T315I mutation remains a significant clinical issue because it is insensitive to all currently available agents. A number of new agents are in development and many hold the promise of activity in T315I-mutated disease. Successful treatment of patients with disease harboring T315I might lie in the effective combination or sequencing of these new agents with existing TKI therapies.

UR - http://www.scopus.com/inward/record.url?scp=74049108720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049108720&partnerID=8YFLogxK

M3 - Review article

C2 - 19778852

AN - SCOPUS:74049108720

VL - 9 Suppl 3

SP - S272-279

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

ER -